COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances. Compass reached unicorn status after becoming the first company in the sector to IPO on the Nasdaq last year.

Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an intellectual property (IP) portfolio including patent applications covering a variety of psychedelic and empathogenic substances. The IP was developed together with inventor Matthias Grill PhD, founder and CEO of MiHKAL GmbH in Basel, Switzerland, who will be working with COMPASS on an exclusive research project to develop new product candidates.

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, the research scientist and film-maker, as a full-time consultant, who will be working primarily at the COMPASS Discovery Center, based at University of the Sciences in Philadelphia (USciences) in the United States. Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need.

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Atai Life Sciences BV

Ameri Holdings

Field Trip Health Ltd

Mind Medicine MindMed

The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.

Time to Buy the Magic Stocks? Magic Mushrooms, That Is.

London, UK – 7 September 2021, Sept. 07, 2021 (GLOBE NEWSWIRE) -- London, UK – 7 September 2021           COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences in September as follows:

COMPASS Pathways to participate in Citi, Morgan Stanley and HC Wainwright investor conferences in September

Axsome Therapeutics

Zogenix

All three stocks on this list can more than double your money according to investment bank analysts who cover them.

3 Biotech Stocks Wall Street Expects to Double Soon

Excellent investing opportunities frequently seem outlandish.

Open-Minded? Buy This Game-Changing Psychedelics Stock Now

Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in COMPASS Pathways (CMPS) Stock?

Talkspace

They're the first pioneers in exciting new markets.

3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge

LONDON, Aug. 11, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business.

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

By 2030, psychedelic therapy will be the gold standard for mental health treatment. And Compass is at the forefront of commercialization.

Growing Psychedelic Interest Will Help Push Compass Pathways Stock Up 3X By 2022

London, UK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2021, and provide an update on recent business developments, on 11 August 2021.

COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021

COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences

COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences

Green Thumb Industries Inc.

Neuronetics Inc

Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments. The post 7 Stocks to Buy if You Think Alternative Therapies Are the Future appeared first on InvestorPlace.

7 Stocks to Buy if You Think Alternative Therapies Are the Future

London, UK – 21 July 2021         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Danielle Schlosser PhD as Senior Vice-President, Clinical Innovation. Dr Schlosser will lead COMPASS's Therapy Research and Training team, bringing her clinical experience in behavioural health and experience in digital health innovation.

Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training

Legislation is starting to open up the industry but investors who are hoping to cash in on its growth opportunities could be waiting a very long time.

Is It Too Early to Invest in Psychedelic Stocks?

London, UK, July 07, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Lars Wilde, President, Chief Business Officer, and Co‑founder, will participate in a fireside chat at 10:10am ET at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on 13 July.

COMPASS Pathways to participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit

COMPASS Pathways joins forces with King's College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK

These companies developing hallucinogens have more than meets the eye.

3 Top Psychedelic Stocks to Buy Now

COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”

Compass Pathways (NASDAQ:CMPS), a biotech company in the psychedelics space, announced it has completed a key milestone on its path to obtaining FDA approval for psilocybin in the treatment of depression. The company reported that it had completed psilocybin administration to all 216 patients that were targeted for Compass' phase IIb clinical trial for treatment-resistant depression.

Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study

Acadia Healthcare

Intra-Cellular Therapies

LifeStance Health Group

Teladoc

One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people's mental health. The next global health crisis may be related to mental health issues such as anxiety and depression, and companies that are focused on mental health could be well-positioned to capitalize on the opportunity.

Pandemic Fallout: 6 Mental Health Stocks To Watch

COMPASS on track to report data in late 2021 COMPASS on track to report data in late 2021

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

These psychedelic stocks have compelling product pipelines and have built up a great head of steam in the past month thanks to the PSY ETF. The post 3 Psychedelics Stocks Getting High Thanks to the Newly Launched PSY ETF appeared first on InvestorPlace.

3 Psychedelics Stocks Getting High Thanks to the Newly Launched PSY ETF

COMPASS Pathways is a business that is trying to treat a serious form of depression by using psilocybin, which is known for its psychoactive effects.

News for COMPASS Pathways Stock (CMPS)